For oncological patients

For oncological patients

Vetom is a recommended supportive therapy for patients with cancer and malignant tumors.

For oncological patients, Vetom 1.1 or 1.23 is recommended for immune activation.
These preparations recover the immune system after surgery, radiotherapy and chemotherapy, reduce the toxic effects during and after treatment.
At the same time, they act as a stimulant of hematopoiesis in oncological diseases and contribute in increasing the effect of medications.

Vetom instantly strengthens the human immune system and helps to cope with  serious illnesses.

The Bacillus subtilis bacteria contained in Vetom 1.1 and Vetom 1.23 multiply in the intestines biologically active substances, which suppress the growth and development of pathogenic and conditionally pathogenic microflora and various types of staphylococcus and streptococcus. As a result of this process, the intestinal microflora is normalized, the walls of the digestive tract are cleansed from indigestible and rotting food residues, which supports the removal of toxins from the body.

After this process, the body is more effectively prepared to absorb biologically active substances and nutrients. The action of Bacillus subtilis improves the absorption and metabolism of iron, calcium, fats, proteins, carbohydrates, triglycerides, amino acids, dipeptides, sugars, salts of bile acids and a balanced pH of the gastrointestinal tract.
By regular use of the product, the body gradually becomes resistant to attacks of harmful bacteria and viruses.

Only the Bacillus subtilis bacteria contained in Vetom 1.1 and Vetom 1.23 are capable of producing interferon , which actively prevents the reproduction of viruses and refers to infected cells in the organism, creating antitumor and immune-stimulating activities.

Interferon alpha-2-leukocyte human

– produced by Bacillus subtilis bacteria enters the bloodstream through the walls of the digestive tract, suppresses cellular viral infection, alters cell membrane ectoplast, prevents adhesion and penetration of virus into the cell. It initiates the synthesis of a number of specific ferments, disrupting the synthesis of viral RNA (RNA) and viral proteins in the cell.

It modifies the cytoskeleton of the cell membrane, prevents the proliferation (proliferation, abundant proliferation, and the formation of neoplasms) of cancer cells. It acts on the synthesis of some oncogenes and inhibits (slows down or stops) tumor growth. It stimulates the activity of so-called “nk killers” that are part of antiviral immunity.

All anti-tumor effects of interferon are divided into direct and indirect. The direct ones have the ability to suppress the growth of tumor cells. The indirect ones are associated with enhancing the ability of immune cells to detect and destroy abnormal cells in the body, ensuring optimal functioning of the immune system.

For oncological patients, the first treatment effect begins after 10 days of use.
This is associated with the fact that after 10 days of use of the preparation, the concentration of so called „nk killer“ cells is multiplied in the blood. To healthy people this can rarely lead to autoimmune reaction. For patients with oncological diseases, on the contrary, this effect is highly desirable and the curative effect of „nk killers“ after 10 days of use of the preparation primarily destroys the cancer cells.

Recommended Vetom Cure 1.1.

Supplemental therapy for oncological patients in capsule form lasts for 30 days. Recommended dosage is 10 capsules a day.
Vetom 1.1 can be re-taken 2 months after the end of use.
After a 10-14 day break,  Vetom 4, 10 capsules a day.
After a 10-14 day break, Vetom 3, 10 capsules a day.
After a 10-14 day break,  Vetom 2, 1 capsule in the morning and 1 capsule in the evening.

Recommended cure for Vetom 1.23

Supplemental therapy for oncological patients in liquid form lasts 30 days. 1 drop of preparation means one dose. 10 drops per day are recommended.
Vetom 1.23 can then be re-taken 2 months after the end of use.
After a 10-14 day break, Vetom 4, 10 capsules a day.
After a 10-14 day break, Vetom 3, 10 capsules a day.
After a 10-14 day break, Vetom 2, 1 capsule in the morning and 1 capsule in the evening.

VETOM Clinical Test Report on Cancer Patients

Evaluation of the efficacy of the Interferon bacterium, which produces VETOM 1.1 as a supportive therapy for patients with malignant tumors. A total of 65 patients were monitored. Most patients were taken into the test during a metastatic disease after previous integrated or combined treatment. All patients in the group were asked for symptomatic treatment and were denied special treatment.
Patients are in the stage 4 – IV. clinical group. All patients underwent chemotherapy. After being released from the hospital to increase their antitumor resistance, patients were given VETOM 1.1 – 1 tablet 10 times a day, 10-15 minutes before meal, for 30 days.
After 1-1.5 months, the patients came back to review and continue the treatment – chemotherapy including hyperthermia. After discharging from the hospital, they continued using VETOM 1.1 as before.
Observations were conducted for over 2 years, and patients were treated with 1 to 8 Vetom 1.1 series.

After treatment with VETOM 1.1, the total serum protein level was significantly increased and returned to normal range. There was also a decrease in ALT and AST transaminases by 32.6 and 28.5%. This may indicate protein recovery and antitoxic liver function.
Within 7 to 10 days after the end of chemotherapy, the overal health status improved, the patients registered: sleep improvement, stool normalization, improvement of hair loss,  weight gain 3.4 kg during 2-3 months.

The analysis made it possible to identify indications for using VETOM 1.1 and VETOM 3.
Recovery of balanced microflora and supplementation of natural immunostimulants to the human body after surgery, radiotherapy and chemotherapy.

Reduction of toxic effects during and after chemotherapy and maintenance of immunotherapy between cycles of chemotherapy.
Protective effect in metastatic liver lesions of concomitant chronic hepatitis B and C, liver cirrhosis.
Immunotherapy for some types of cancers: kidney, bladder, skin, colon, melanoma, lymphoma.

This means that the bacterial preparation VETOM 1.1, producing the interferon immunostimulant and VETOM 3, can be used as a prophylactic treatment to reduce the toxic effects of chemotherapy and radiation therapy, it also has regenerative and detoxifying effects and an effect on restoring the antitumor activity of the organism.